Research & Literature

Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.

Pfau M, Fassnacht-Riederle H, Becker MD, et al.

Ophthalmic research 2015; (54(3)):150-6 doi:10.1159/000439223.

Central Retinal Vein Occlusion: A Review of Current Evidence-based Treatment Options.

Patel A, Nguyen C, Lu S

Middle East African journal of ophthalmology 2016; (23(1)):44-8 doi:10.4103/0974-9233.173132.

Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.

Al-Rashaed S, Alsulaiman SM, Alrushood AA, et al.

Middle East African journal of ophthalmology 2016; (23(1)):60-3 doi:10.4103/0974-9233.171756.

Optical Coherence Tomography Angiography of the Foveal Avascular Zone in Retinal Vein Occlusion.

Wons J, Pfau M, Wirth MA, et al.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 2016; (235(4)):195-202 doi:10.1159/000445482.

Retinal Capillary Network and Foveal Avascular Zone in Eyes with Vein Occlusion and Fellow Eyes Analyzed With Optical Coherence Tomography Angiography.

Adhi M, Filho MA, Louzada RN, et al.

Investigative ophthalmology & visual science 2016; (57(9)):OCT486-94 doi:10.1167/iovs.15-18907.

Location of a Dexamethasone Implant at the Macula after Intravitreal Injection in a Silicone Oil-Filled Eye.

Esenulku CM, Gunay M

Case reports in ophthalmological medicine 2016; (2016()):5107652 doi:10.1155/2016/5107652.

ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ERA.

Tam EK, Golchet P, Yung M, et al.

Retina (Philadelphia, Pa.) 2018; (38(2)):292-298 doi:10.1097/IAE.0000000000001546.

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Chatziralli I, Theodossiadis G, Moschos MM, et al.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2017; (255(6)):1093-1100 doi:10.1007/s00417-017-3613-1.

Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion.

Lee KH, Kang EC, Koh HJ

Yonsei medical journal 2017; (58(3)):676-678 doi:10.3349/ymj.2017.58.3.676.

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

Chatziralli I, Theodossiadis G, Theodossiadis P

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2017; (255(7)):1459-1460 doi:10.1007/s00417-017-3682-1.

BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.

Kitagawa S, Yasuda S, Ito Y, et al.

Retina (Philadelphia, Pa.) 2018; (38(7)):1354-1360 doi:10.1097/IAE.0000000000001707.

Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.

Wittström E

The open ophthalmology journal 2017; (11()):89-102 doi:10.2174/1874364101711010089.

CONN SYNDROME PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION.

Atik A, Wilson D, Essex RW

Retinal cases & brief reports 2020; (14(1)):20-22 doi:10.1097/ICB.0000000000000611.

USE OF THE ISCHEMIC INDEX ON WIDEFIELD FLUORESCEIN ANGIOGRAPHY TO CHARACTERIZE A CENTRAL RETINAL VEIN OCCLUSION AS ISCHEMIC OR NONISCHEMIC.

Thomas AS, Thomas MK, Finn AP, Fekrat S

Retina (Philadelphia, Pa.) 2019; (39(6)):1033-1038 doi:10.1097/IAE.0000000000002126.

Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report.

Grzybowski A, Elikowski W, Gaca-Wysocka M

Medicine 2018; (97(1)):e9255 doi:10.1097/MD.0000000000009255.

INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial.

Casselholm de Salles M, Amrén U, Kvanta A, Epstein DL

Retina (Philadelphia, Pa.) 2019; (39(7)):1370-1376 doi:10.1097/IAE.0000000000002171.

Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.

Holekamp NM, Campbell J, Almony A, et al.

American journal of ophthalmology 2018; (191()):83-91 doi:10.1016/j.ajo.2018.04.010.

Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.

Sangroongruangsri S, Ratanapakorn T, Wu O, et al.

Expert review of clinical pharmacology 2018; (11(9)):903-916 doi:10.1080/17512433.2018.1507735.

CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes.

Rothman AL, Thomas AS, Khan K, Fekrat S

Retina (Philadelphia, Pa.) 2019; (39(10)):1917-1924 doi:10.1097/IAE.0000000000002278.

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion.

Nghiem-Buffet S, Glacet-Bernard A, Addou-Regnard M, et al.

Journal of ophthalmology 2018; (2018()):8656495 doi:10.1155/2018/8656495.

Analysis of Morphologic and Functional Outcomes in Macular Edema due to Central Retinal Vein Occlusion Treated with Intravitreal Dexamethasone Implant.

Niro A, Sborgia G, Sborgia A, et al.

Journal of ophthalmology 2018; (2018()):5604632 doi:10.1155/2018/5604632.

Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion.

Berry D, Thomas AS, Fekrat S, Grewal DS

Ophthalmology. Retina 2018; (2(11)):1125-1132 doi:10.1016/j.oret.2018.04.019.

OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.

Tang F, Qin X, Lu J, et al.

Retina (Philadelphia, Pa.) 2020; (40(4)):773-785 doi:10.1097/IAE.0000000000002444.

Efficacy of panretinal laser in ischemic central retinal vein occlusion: A systematic review.

Li C, Wang R, Liu G, et al.

Experimental and therapeutic medicine 2019; (17(1)):901-910 doi:10.3892/etm.2018.7034.

Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor.

Li Y, Hu D, Lv P, et al.

European journal of ophthalmology 2020; (30(3)):500-505 doi:10.1177/1120672119832785.

Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors.

Spooner K, Fraser-Bell S, Hong T, Chang AA

BMJ open ophthalmology 2019; (4(1)):e000249 doi:10.1136/bmjophth-2018-000249.

IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION.

Khayat M, Wright DM, Yeong J, et al.

Retina (Philadelphia, Pa.) 2020; (40(6)):1098-1109 doi:10.1097/IAE.0000000000002571.

REDUCTION OF POSTINTRAVITREAL INJECTION PAIN USING ICE: An Open-Label Interventional Randomized Controlled Trial.

Yahalomi T, Hecht I, Lagstein O, et al.

Retina (Philadelphia, Pa.) 2020; (40(7)):1434-1438 doi:10.1097/IAE.0000000000002608.

Central retinal vein occlusion associated with platelet activation.

Citirik M

Therapeutic advances in ophthalmology 2019; (11()):2515841419864844 doi:10.1177/2515841419864844.

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.

Hykin P, Prevost AT, Vasconcelos JC, et al.

JAMA ophthalmology 2019; (137(11)):1256-1264 doi:10.1001/jamaophthalmol.2019.3305.

Clinical Features of Combined Central Retinal Artery and Vein Occlusion.

Wang H, Chang Y, Zhang F, et al.

Journal of ophthalmology 2019; (2019()):7202731 doi:10.1155/2019/7202731.

Comparison of vascular endothelial growth factor inhibitors on macular oedema secondary central retinal vein occlusion.

Teo KYC, Mohla A, Cheung CMG

Eye (London, England) 2020; (34(2)):221-222 doi:10.1038/s41433-019-0707-5.

Evaluation of the Initial Optical Coherence Tomography Parameters in Anticipating the Final Visual Outcome of Central Retinal Vein Occlusion.

Ozer MD, Batur M, Mesen S, et al.

Journal of current ophthalmology 2020; (32(1)):46-52 doi:10.4103/JOCO.JOCO_47_20.

Predictive values of initial semi-quantitative assessment of relative afferent pupillary defect for neovascularization in central retinal vein occlusion.

Ducloyer JB, Bensaber S, Khanna RK, et al.

Acta ophthalmologica 2021; (99(2)):215-220 doi:10.1111/aos.14544.

Hyperreflectivity of Inner Retinal Layers as a Quantitative Parameter of Ischemic Damage in Acute Retinal Vein Occlusion (RVO): An Optical Coherence Tomography Study.

Furashova O, Matthè E

Clinical ophthalmology (Auckland, N.Z.) 2020; (14()):2453-2462 doi:10.2147/OPTH.S260000.

Retinal vein occlusion in COVID-19: A novel entity.

Sheth JU, Narayanan R, Goyal J, Goyal V

Indian journal of ophthalmology 2020; (68(10)):2291-2293 doi:10.4103/ijo.IJO_2380_20.

The impact of structural optical coherence tomography changes on visual function in retinal vein occlusion.

Michl M, Liu X, Kaider A, et al.

Acta ophthalmologica 2021; (99(4)):418-426 doi:10.1111/aos.14621.

Risk factors for central retinal vein occlusion in young adults.

Chen TY, Uppuluri A, Zarbin MA, Bhagat N

European journal of ophthalmology 2021; (31(5)):2546-2555 doi:10.1177/1120672120960333.

Predicting response of ischemic central retinal vein occlusion to bevacizumab injections: 1 year follow-up.

Segal O, Mimouni M, Rabina G, et al.

International ophthalmology 2021; (41(2)):533-540 doi:10.1007/s10792-020-01604-0.

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.

Korobelnik JF, Larsen M, Eter N, et al.

American journal of ophthalmology 2021; (227()):106-115 doi:10.1016/j.ajo.2021.01.027.

Neovascular glaucoma - A review.

Senthil S, Dada T, Das T, et al.

Indian journal of ophthalmology 2021; (69(3)):525-534 doi:10.4103/ijo.IJO_1591_20.

Photocoagulation for retinal vein occlusion.

Hayreh SS

Progress in retinal and eye research 2021; (85()):100964 doi:10.1016/j.preteyeres.2021.100964.

Central Retinal Vein Occlusion in a 46-Year-Old Man with COVID-19: Case Report and Review of the Literature.

Miller CG, Kim BJ

Case reports in ophthalmology 2021; (12(2)):646-652 doi:10.1159/000517417.

Impact of Anxiety Levels and Sleep Patterns on Perceived Pain During Intravitreal Bevacizumab Injections.

Wieder MS, Szlechter M, Fischman N, et al.

Ophthalmic surgery, lasers & imaging retina 2021; (52(9)):498-504 doi:10.3928/23258160-20210819-02.

Relationship between stereopsis and vision-related quality of life following intravitreal ranibizumab injections for central retinal vein occlusion.

Okamoto F, Tomioka M, Murakami T, et al.

Scientific reports 2021; (11(1)):20475 doi:10.1038/s41598-021-00094-z.

CALRETICULIN MUTATION ASSOCIATED WITH BILATERAL CENTRAL RETINAL VEIN OCCLUSION IN A YOUNG WOMAN.

Kabanovski A, Donaldson L, Koushan K, Margolin E

Retinal cases & brief reports 2023; (17(4)):389-391 doi:10.1097/ICB.0000000000001200.

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion: A protocol for systematic review and network meta-analysis.

Liu Z, Wang S, Ma A, Zhao B

Medicine 2021; (100(52)):e28283 doi:10.1097/MD.0000000000028283.

Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.

Gurudas S, Patrao N, Nicholson L, et al.

JAMA ophthalmology 2022; (140(2)):143-150 doi:10.1001/jamaophthalmol.2021.5619.

Retinal vein occlusion following COVID-19 vaccination.

Peters MC, Cheng SSH, Sharma A, Moloney TP

Clinical & experimental ophthalmology 2022; (50(4)):459-461 doi:10.1111/ceo.14056.

Central retinal thickness changes and risk of neovascular glaucoma after intravitreal bevacizumab injection in patients with central retinal vein occlusion.

Lee YH, Kim YC

Scientific reports 2022; (12(1)):2051 doi:10.1038/s41598-022-06121-x.

The pathological association between the anterior eye segment and the retina in a murine model of neovascular glaucoma.

Nishinaka A, Tanaka M, Aoshima K, et al.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022; (36(6)):e22323 doi:10.1096/fj.202101917R.

Etiology, pathogenesis, and diagnosis of neovascular glaucoma.

Călugăru D, Călugăru M

International journal of ophthalmology 2022; (15(6)):1005-1010 doi:10.18240/ijo.2022.06.20.

A review of the management of central retinal artery occlusion.

Madike R, Cugati S, Chen C

Taiwan journal of ophthalmology 2022; (12(3)):273-281 doi:10.4103/2211-5056.353126.

Vision-related quality of life and subscale items following intravitreal ranibizumab injections for central retinal vein occlusion.

Okamoto F, Murakami T, Sugiura Y, et al.

Japanese journal of ophthalmology 2023; (67(1)):59-65 doi:10.1007/s10384-022-00949-6.

The role of optical coherence tomography angiography in distinguishing ischemic versus non-ischemic central retinal vein occlusion.

An W, Zhao Q, Yu R, Han J

BMC ophthalmology 2022; (22(1)):413 doi:10.1186/s12886-022-02637-y.

Characteristics of Central Retinal Vein Occlusion in African Americans.

Kiew SY, Thomas GN, Thomas AS, Fekrat S

Journal of vitreoretinal diseases 2020; (4(3)):186-191 doi:10.1177/2474126419882829.

Intravitreal Injection Therapy: Current Techniques and Supplemental Services.

Lam LA, Mehta S, Lad EM, et al.

Journal of vitreoretinal diseases 2021; (5(5)):438-447 doi:10.1177/24741264211028441.

Retinal Vascular Occlusion and Underlying Generalized Vascular Diseases.

Feltgen N, Agostini H

Klinische Monatsblatter fur Augenheilkunde 2023; (240(9)):1071-1076 doi:10.1055/a-2097-0938.

Central retinal vein occlusion in young population: risk factors and outcomes.

Berguig J, Abdelmassih Y, Azar G, et al.

Frontiers in medicine 2023; (10()):1180234 doi:10.3389/fmed.2023.1180234.

Acute onset of decreased vision after violently vomiting: A case report.

He H, Wang Z, Zhou H, Jin ZB

European journal of ophthalmology 2024; (34(2)):NP87-NP91 doi:10.1177/11206721231208665.

Characteristics of macular edema associated with retinal vein occlusion showing poor anatomic response to three loading anti-vascular endothelial growth factor injections: an optical coherence tomography analysis.

Johari M, Attar A, Eghtedari D, Razavizadegan SA

BMC ophthalmology 2024; (24(1)):30 doi:10.1186/s12886-024-03298-9.

Rates of endophthalmitis before and after transition from povidone-iodine to aqueous chlorhexidine asepsis for intravitreal injection.

Stephenson KA, Merkur A, Kirker A, et al.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024; (59(6)):424-429 doi:10.1016/j.jcjo.2024.01.012.

Vision-related quality of life in patients with retinal vein occlusion.

Ramin S, Rostami F, Ahmadieh H, et al.

International ophthalmology 2024; (44(1)):114 doi:10.1007/s10792-024-02916-1.

[Current views on pathogenesis and treatment of neovascular glaucoma].

Fedoruk NA

Vestnik oftalmologii 2024; (140(3)):110-116 doi:10.17116/oftalma2024140031110.

Efficacy and Safety of Laser Therapy on Ischemic Central Retinal Vein Occlusion: A Systematic Review and Analysis of Clinical Studies.

Alotaibi GF, Seraj H, AlMulihi QA, et al.

Cureus 2024; (16(6)):e62292 doi:10.7759/cureus.62292.

Evaluation of Anatomical and Tomographic Biomarkers as Predictive Visual Acuity Factors in Eyes with Retinal Vein Occlusion Treated with Dexamethasone Implant.

Covello G, Maglionico MN, Figus M, et al.

Journal of clinical medicine 2024; (13(15)) doi:10.3390/jcm13154533.

Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.

Kulikov AN, Vasiliev AS, Kalinicheva YA, Maltsev DS

BMC ophthalmology 2024; (24(1)):369 doi:10.1186/s12886-024-03650-z.

Pain perception during intravitreal injections is related to the timing of instilling anesthetic eyedrops.

Voichanski S, Totah H, Hanhart J

International ophthalmology 2024; (44(1)):383 doi:10.1007/s10792-024-03315-2.

Optic disc edema and visual loss from paracentral acute middle maculopathy mimicking optic neuritis.

Pereira CR, Benassi TSA, Mello LGM, et al.

Arquivos brasileiros de oftalmologia 2024; (88(2)):e20230185 doi:10.5935/0004-2749.2023-0185.

Posterior Vitreous Detachment and Risk of Neovascular Glaucoma in Eyes with Prior Retinal Vascular Occlusions.

Palmer LD, Peterson JD, Evans JK, et al.

Ophthalmology and therapy 2024; (13(11)):3013-3024 doi:10.1007/s40123-024-01039-1.

Clopidogrel therapy in nonischemic central retinal vein occlusion: A case report and therapeutic insight.

Al Ghaithi H, Al Hinai A, Al Abri M, Al-Futaisi A

Oman journal of ophthalmology 2024; (17(3)):380-383 doi:10.4103/ojo.ojo_83_24.

Risk of Adverse Systemic Events in Retinal Vein Occlusion.

Albrecht EA, Shukla P, Zhao AH, et al.

Ophthalmology. Retina 2025; (9(11)):1090-1097 doi:10.1016/j.oret.2025.05.005.

Evaluation of optical coherence tomography angiography role in differentiating ischemic and non-ischemic central retinal vein occlusion.

Elhabiby IAM, Mandour SS, Nage SAM

International ophthalmology 2025; (45(1)):374 doi:10.1007/s10792-025-03731-y.

Young-Onset Central Retinal Vein Occlusion with Antiphospholipid Syndrome and Hypophysitis.

Kawata M, Sawamura H, Aoki S, et al.

Case reports in ophthalmology 2025; (16(1)):693-702 doi:10.1159/000548080.

Current Understanding of Retinal Vein Thrombosis in Older Adults: A Review of the Literature.

Smekalkina LV, Safonicheva OG, Kabardina EV, et al.

Clinical interventions in aging 2025; (20()):2399-2407 doi:10.2147/CIA.S548403.

Central Retinal Vein Occlusion in Pregnancy: A Rare Case Report.

Manade VV, Kotecha MR, Sangwan JN, Chodvadiya S

Annals of African medicine 2026; doi:10.4103/aam.aam_636_25.